Business Wire

NTT: Conclusion of a Cooperation Agreement with ITER

Share

NTT Corporation (NTT, President & CEO: Jun Sawada) concluded a Cooperation Agreement on the ITER Project with the ITER International Fusion Energy Organization (ITER Organization).
By supporting the ITER Project, which has the objective of building the world’s first experimental hydrogen fusion reactor, NTT will accelerate “Development of innovative environment and energy technologies”, and contribute to the reduction of the environmental impact of customers, companies and society.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200514005951/en/

ITER construction site in Provence in the south of France (Photo: Business Wire)

ITER construction site in Provence in the south of France (Photo: Business Wire)

1. Background
The ITER Project is an extraordinarily large international project that has the objective of building the world’s first experimental hydrogen fusion reactor (ITER) to prove the scientific and technical feasibility of the fusion energy for peaceful purposes. The ITER Organization, an international organization with seven members – Japan, the European Union, Russia, the United States, South Korea, China, and India – is engaged in the ITER Project.

NTT is aiming at “Zero Environmental Impact” by supporting customers, enterprises, and society in reducing their impact on the environment through our R&D aimed at creating innovations that break through conventional limitations and by pursuing business activities designed to decrease deleterious effects on the environment. For example, NTT is preparing to establish the Space Environment and Energy Laboratories, which will undertake research with the goal of creating innovative energy and environmental technologies.
NTT assumes the use of photonic technologies developed for IOWN* concept, and will work to extend the current ICT technologies, which would benefit the ITER Project.
*IOWN (Innovative Optical and Wireless Network) is a future communications infrastructure to create a smarter world by using cutting-edge technologies like photonics and computing technologies.
https://www.rd.ntt/e/iown/

2. Scope of Cooperation
Under the strategic intent of this Cooperation Agreement, NTT will collaborate in the following areas.

  • Exploration of innovative future Information and Communication Technology, including ultra-high-speed network, ultra-low latency network connectivity, data storage, computing, and global network infrastructure.
  • Exploration of the concept “IOWN” including All-Photonics Network, Digital Twin Computing, and Cognitive Foundation.

This is the first time that the ITER Organization has signed a Long Term Non-Commercial Cooperation Agreement with a private Japanese company. As a general ICT player capable of providing full-stack, full-lifecycle services on a global scale, the NTT Group will collaborate on information distribution and control platforms in preparation for ITER’s first plasma in 2025 and beyond.
NTT will work out the details and conclude an implementation agreement.

3. Executive statements
“With an aim of achieving zero environmental impact, NTT is conducting R&D to create the innovations needed to achieve this goal, and carrying out its business activities in a manner that reduces its effects on the environment. Safe and permanent fusion energy is one of the most promising technologies in this important endeavor. We believe that NTT’s groundbreaking R&D activities, including IOWN, and our ability to construct global infrastructure can make a valuable contribution to the ITER Organization, a leading research entity in this area. Under this agreement, we will work closely with the ITER Organization to demonstrate the feasibility of fusion power at an industrial scale for the first time in human history.”
-Jun Sawada, President & CEO, NTT

“We, with the seven ITER Members, believe that fusion power can become a clean and safe vital contributor to the global energy mix for our civilization starting in this century for numerous millennium, and the progress of the ITER Project is essential for that path. I am pleased to have global ICT companies like NTT as one of our long-term non-commercial collaboration partners, with the solid capacity to develop advanced global ICT technologies as well as the capability to envision innovative future technologies strategies such as the IOWN concept that fusion will definitively need.”
-Bernard Bigot, Director-General, the ITER Organization

About NTT
NTT believes in resolving social issues through our business operations by applying technology for good. We help clients accelerate growth and innovate for current and new business models. Our services include digital business consulting, technology and managed services for cybersecurity, applications, workplace, cloud, data center and networks all supported by our deep industry expertise and innovation.
As a top 5 global technology and business solutions provider, our diverse teams operate in 88 countries and regions and deliver services to over 190 of them. We serve 85% of Fortune Global 100 companies and thousands of other clients and communities around the world.

Contact information

Media contacts
NTT
Press Relations
Yuzo Aramaki
ntt-cnr-ml@hco.ntt.co.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 15:00:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25th European Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leuke

Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 15:00:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the 25th European Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 15:00:00 EESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 15:00:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo

LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 14:57:00 EESTPress release

LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing

Boehringer Ingelheim receives positive CHMP opinion for a third nintedanib indication in pulmonary fibrosis129.5.2020 14:38:00 EESTPress release

Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending an additional indication for nintedanib in adults for the treatment of other chronic fibrosing interstitial lung diseases with a progressive phenotype beyond IPF.1 The opinion is based on the positive results of the INBUILD® phase III trial, the first study to evaluate adults with a broad range of chronic fibrosing interstitial lung diseases (ILDs) and a progressive disease behaviour.2 This follows the FDA’s and Health Canada’s approval of nintedanib as the first treatment for the same patient population.3,4 Interstitial lung diseases encompass a large group of more than 200 disorders that may involve the threat of pulmonary fibrosis – an irreversible scarring of lung tissue that negatively impacts lung function.5 People living with fibrosing ILD can develop a progressive phenotype, leading to lung functio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom